Clinical Trial: Melflufen (not Melphalan) and dexamethasone for Relapsed/Refractory Myeloma

Melflufen is a modified version of melphalan. Multiple myeloma cells have enzymes that are overexpressed at very high levels. Melflufen is trapped at higher concentrations within diseased cells, so it is more targeted than melphalan. According to the company developing the drug, Oncopeptides AB in Sweden, melflufen has a 50-100x higher anti-tumor potency over melphalan. The new drug melflufen is now being tested with dexamethasone for patients with relapsed/refractory multiple myeloma. One of the study goals is to use the drug for patients who have become refractory to pomalidomide and/or daratumumab. Patients will be treated with melflufen on Day 1 and then dex on days 1, 8, 15 and 22 of a 28-day cycle. To find this clinical trial on SparkCures, click here: Melflufen and Dex Clinical Trial
Melflufen is a modified version of melphalan. Multiple myeloma cells have enzymes that are overexpressed at very high levels. Melflufen is trapped at higher concentrations within diseased cells, so it is more targeted than melphalan. According to the company developing the drug, Oncopeptides AB in Sweden, melflufen has a 50-100x higher anti-tumor potency over melphalan. The new drug melflufen is now being tested with dexamethasone for patients with relapsed/refractory multiple myeloma. One of the study goals is to use the drug for patients who have become refractory to pomalidomide and/or daratumumab. Patients will be treated with melflufen on Day 1 and then dex on days 1, 8, 15 and 22 of a 28-day cycle. To find this clinical trial on SparkCures, click here: Melflufen and Dex Clinical Trial

about the author
Jennifer Ahlstrom
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can contribute to cures by joining HealthTree Cure Hub and joining clinical research. Founder and CEO of HealthTree Foundation.
More on Navigating Your Health
Trending Articles





Get the Latest Multiple Myeloma Updates, Delivered to You.
By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.